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Introduction: 
 The Immune system is the set of defenses in the body that protects us from 
becoming ill. It is made up of many different types of cells and substances, all of 
which work together to help us heal when we have been injured. The immune system 
recognizes, fights, and remembers foreign invaders like bacteria or viruses, which can 
cause illness in our bodies. Such invaders are called “pathogens”. Our immune system 
is responsible for defending the body against a wide and constantly changing range of 
possible pathogens. The number of cell types, molecular interactions and soluble 
factors that are involved in the immune response are not only responsible for an 
organism’s defense against infections but also play an important role in self-
maintenance and antitumor responses. When the immune system hits the wrong target 
or is crippled, it can result in disease, including allergy, AIDS, arthritis and many 
more (1, 2).  
 The immune system is amazingly complex; it can target unique features of 
pathogens by tailoring specific response to that pathogen. In order to do this, cells in 
the immune system must first have the capacity to recognize a pathogen and convert 
that recognition into action. This is done by a variety of receptors on the surface of 
immune cells (1).   
 Innate immunity is the first line of defense against invading pathogens. The 
cells of the innate immune system can detect pathogens using pattern recognition 
receptors. Pattern recognition receptors are encoded within the germline and bind to 
molecules characteristic of larger groups of pathogens. For instance, Toll Like 
receptor (TLR) 2 and 4 can bind lipopolysaccharide (LPS). LPS is a component of the 
outer membrane of all gram negative bacteria and is thus a molecular pattern that is a 
signature of this group of bacteria, or a Pathogen Associated Molecular Pattern 
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(PAMP)(3). Upon binding of LPS to the TLR 2/4 dimers on the surface of an innate 
immune cell, it initiates a cascade of intracellular events leading to the production of 
cytokines, intercellular signaling molecules, which ultimately results in inflammation. 
In this way the innate immune system can activate a defense mechanism quickly, but 
it is not a defense tailored to that specific pathogen, TLR does not distinguish between 
the LPS of E. coli and P. aeruginosa, so the innate system, while it can initiate a 
response, is not capable of a pathogen specific response and it does not provide 
lasting immunological memory (1, 2).  
 The adaptive immune system on the other hand does have the capacity to 
recognize specific features of a pathogen and create immunological memory, 
producing a life-long memory of our previous infections. The adaptive immune 
system is made of B and T lymphocytes. B and T lymphocytes are similar in many 
ways and I will focus here on B-lymphocytes since they are the focus of my research. 
 To effectively eliminate the variety of pathogens that an individual may 
encounter in their lifetime, the immune system has evolved to recognize many 
different antigens. Within adaptive immunity there are also safe guards where the 
self-reactive or defective cells are eliminated (1). The removal of such cells is by 
apoptosis, which is a form of cell suicide characterized by an orderly breakdown of 
the cell to limit the leakage of cytoplasmic components that could cause 
inflammation. Apoptosis can be initiated by signaling through specific cell surface 
molecules and is carried out by downstream mediators. While several model systems 
of apoptosis do exist, one pathway in developing avian B-cells, which is activated by 
the cell surface molecule chB6, has yet to be elucidated(4,5). The Funk lab has been 
interested in the role of alloantigen chB6 (Bu1) in the developing of B cells within the 
bursa and has shown that chB6 can trigger apoptosis. When an agonist antibody 
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stimulates chB6, rapid cell death follows and it is presumed that there is an 
endogenous ligand. Funk lab has evidence which suggests that there is certain section 
of chB6 molecule that is essential in initiating a death signal inside the cell (Funk 
unpublished). Within this death signaling region is a SH3 binding site and I was 
interested in testing whether mutating this SH3 binding site affects the cell death. This 
project furthers our understanding of the biology of chB6.  
 
Literature review  
 
                                    B-lymphocytes are responsible for the manufacturing of antigen 
recognition molecules known as immunoglobulin (Ig), also called antibodies. To 
efficiently identify and eliminate the variety of pathogens that an individual may 
encounter, the immune system has evolved to recognize many different antigens by 
creating a vast array of cells, each bearing a unique receptor (the B Cell receptor 
which includes the antibody molecule) for a particular antigen. When a B cell bearing 
a receptor that binds to an antigen with high affinity encounters that antigen, the B 
cell will divide, creating a series of descendants all bearing an antibody of identical 
specificity and this process is known as clonal selection(1).  Some of these 
descendants become memory cells and some become plasma cells. Plasma cells 
secrete their antibody and thus help to effect an immune response to the antigen. 
These secreted antibody molecules have two main functions: to bind to an antigen and 
recruit different cells and molecules to destroy the foreign antigen after the antibody 
has bound to it(1).  
  Since each B cell can make only one type of antibody, millions of B cells are 
required to counter the vast array of potential pathogens. It has been estimated that 
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there are 10
8
 antigens that an individual may be exposed to, thus production of a large 
variety of antibodies is necessary. This diversity is generated by a process called V 
(D) J gene rearrangement (1,6).    
  To understand how antibody diversity is created, it is first necessary to 
understand the physical structure of an antibody protein. Antibody molecules are Y 
shaped molecules, which consists of three equal sized portions connected by a flexible 
tether. All antibodies are constructed in the same way from pairing heavy and light 
polypeptides and the generic term immunoglobulin is used for all such proteins. 
Immunoglobulin molecule is composed of two types of protein chain: heavy chains 
and light chains, each immunoglobulin molecule is made up of two heavy chains and 
two light chains which are joined together by disulfide bonds so that each heavy chain 
is linked with a light chain and the two heavy chains are linked together (Figure 1,2).  
Both the light and heavy chains contain constant and variable regions.  
The variable regions of each antibody molecule are different from of all other 
antibody molecules and this is the specific region which binds to an antigen (Ag), 
therefore the variable region can have almost infinite number of forms. It is the 
variable region that determines the specificity to the antigen. In both the light and 
heavy chains, amino acid sequence variability is concentrated within three segments 
known as hyper variable loops or complementary determining regions. Thus when an 
antigen binds to an antibody each will have a shape that is complementary to the 
other, like a hand fitting a glove. There are almost 108 antigens that any individual 
may be exposed to and due to this high number, the production of a large variety of 
antibodies is necessary. The Human genome contains approximately only 20,000(1) 
genes and due to this limited amount of genetic material available, B cells undergoes 
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series of random gene rearrangement within their antibody to create a huge diversity 
of unique antibodies(1). 
  Gene rearrangement occurs in the exon that encodes the variable region of an 
antibody, as this is where the antigen-binding site is situated. The variable region of 
the heavy chain undergoes gene rearrangement followed by the variable region of a 
light chain.  Three separate gene segments encode the heavy chain variable region: 
The variable (VH) gene segment, the diversity (DH) gene segment and joining (JH) 
gene segment. In heavy chain rearrangement, a (DH) gene segment first is joined to a 
(JH) segment; then a (VH ) segment rearranges with a rearranged (DJH ) segment to 
form a complete heavy chain variable region exon.  The joining of these regions 
constructs continuous exons, which encodes the entire heavy chain variable region. 
(Figure 1,2) .The light chain rearranges in a similar fashion, but it contains only V and 
J segments(1). 
  Since there are many functional gene segments for immunoglobulin and any 
of these segments is capable of rearranging with each other, a diverse group of 
antibodies can be produced, In humans, the heavy chain locus consists of 65 
functional (VH) segments, 27 (DH) segments and 6 (JH) segments, therefore about 
11,000 different VH regions are possible just based on the recombination of multiple 
gene segments (65 X 27 X 6). Once the heavy chain is rearranged, light chain 
rearrangement begins, there are two types of light chain: kappa () and lambda (), 
each containing distinct V and J gene segments. In the human Kappa light chain, there 
are 40 functional V segments and 5 J segments making 200 combinations. In lambda 
light chains there are 30 functional V segments and 4 J segments making 120 
combinations. This sums up to 320 different light chains and 11,000 heavy chains 
resulting in 3.5 x 10
6 
antibodies with diverse specificities based solely on the number 
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of gene segments available(1). Additional mechanisms during the recombination 
process create diversity by subtly altering the exact recombination points, meaning 
that even if the same VL and JL recombined in different B cells, they would likely 
create a different sequence across the junction of the gene segments. For example, the 
enzyme terminal deoxynucleotidyl transferase (TdT) can add non-templated 
nucleotides during the recombination event. In all, these mechanisms are quite 
powerful and can create an estimated more than 10
12  
distinct antibody molecules.(1,2, 
6, 7) 
  When we encounter an infection, at least a few of the B cells recognize the 
foreign molecule and are able to mount a response. It is this diversity of B cells that 
helps us to respond to a wide range of infections (1). It is interesting to note that gene 
diversification in avian species occurs somewhat differently. In birds, B cells develop 
in a primary lymphoid organ, the bursa of Fabricius, rather than the bone 
marrow(8,9). The avian Ig locus has only few available D segments, and only one 
active V and J segment for the heavy chain gene (8). Similarly there is only one active 
V and J for the light chain gene. Therefore gene rearrangement can result in limited 
receptor diversity in chicken. In order to generate diversity among immunoglobulin in 
avian species, B-cells undergo somatic gene conversion. B cell precursors that have 
successfully undergone V (D) J rearrangement in the embryonic spleen migrate 
towards the bursal epithelial basement membrane from the spleen and proliferate in 
the follicles of bursa (6-8). During the proliferation in the bursa pseudo genes, which 
are non-functional V gene segments, are introduced into the rearranged gene, thus 
creating diversity in the receptors. Gene conversion can occur multiple times in 
multiple positions in the same B cell clone during development in the bursa(7,8)  
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 Rabbits also undergo this type of B cell diversification in order to generate 
their antibody repertoire, however this process takes place in the appendix(10). 
 
                              Problem of antibodies  
  While diversity in the antibody repertoire is essential to counter an ever-
changing group of pathogens, it creates certain problems. The rearrangement events 
described above use varied gene segments and non-templated nucleotides to generate 
as much diversity in the antibody repertoire as possible.  However, this randomness 
also means that we can create antibodies that would attack our own cells.  It also 
means that some B cells will be defective and unable to produce a functional antibody 
protein(2). Non –functional proteins may arise when the rearrangement process 
creates a premature stop codon, for example.  This results in production of a non-
productive gene rearrangement and will ultimately result in B cells that cannot 
produce a functional immunoglobulin molecule. Among those cells that successfully 
generate an antibody molecule, some of them can be auto reactive, binding to self-
molecules. These cells bear Ig that could potentially bind to self-molecules and will 
initiate an attack on one’s own cells. This lack of tolerance to our own tissues could 
lead to autoimmune diseases where our immune system attacks us. Both non-
functional and potentially auto reactive cells must be eliminated. Evidence indicates 
that they are eliminated via apoptosis to minimize damage to surrounding cells and 
tissues, and prevent a defective B cell from reaching peripheral circulation where it 
could become dangerous (11). In studies of both mouse and chicken, it is estimated 
that 90 - 95% of B cells undergo apoptosis during development and only 5% migrate 
out to the periphery to become a mature B cell capable of responding to 
antigen(11,12).   
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  Given the challenge of creating a diverse antibody repertoire, it is not as 
simple as just deleting potentially dangerous cells. If immature B cells in bone 
marrow show any kind of specificity for a self-molecule, the problem can be 
corrected through receptor editing and clonal deletion (13-19). As I will discuss later, 
B cells receive signals via their surface bound antibody molecules and the nature of 
this signal can influence how B cells behave. In receptor editing, light chains can 
make several successive rearrangements. Remember that the antibody specificity is 
determined by the variable regions of both the heavy and light chains; by replacing 
the light chain it might make the antibody non-self-reactive and thus save the B cell. 
(13,14,20).The more common among path is clonal deletion; where self-reactive cells 
receive a signal to undergo cell death via apoptosis and are eliminated prior to 
maturing into functional B cells. Escape from apoptosis can lead to the presence of 
auto reactive lymphocytes and also growth of leukemic cells due to uncontrolled 
growth of cells or failure to die when given an apoptotic signal.(20,21)  
  Cell surface molecules such as Fas (CD95) and others in the tumor necrosis 
factor receptor (TNFR)  family are known to be involved in the deletion of the mature 
B cells in the periphery via initiating apoptotic signals(22,23).  Thus when a mature B 
cell encounters a portion of self-molecule that it shows an affinity for, one of four 
major mechanisms occurs to prevent autoimmunity. First the cell becomes inactive or 
anergic which results in the down regulation of surface immunoglobulin expression 
and inhibition of the signaling pathways.  On the other hand cells may be restricted 
from interacting with the T cells, a signal that is crucial for a proper immune response 
and also B cell survival, thus fails to interact with T cells can ultimately inhibit any 
signals given to B cell. In yet other mechanisms, signals that normally prevent 
apoptosis from occurring may be down regulated, or signals that promote apoptosis 
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may be up regulated. The end result for all these mechanism is death of auto reactive 
B cells. If any of these fails, it can result in auto immunity(1). Also it is interesting to 
note that any deregulation of TNF production, whether it is low or high, can also lead 
to autoimmune diseases (24). In fact recent studies have shown that dualistic, pro 
inflammatory and immune or disease suppressive role for TNF in these conditions. 
Recent studies have also shown that blocking of TNF in autoimmune prone chronic 
inflammatory diseases can lead to unpredictable outcomes. For example studies have 
shown that blockade of TNF in human rheumatoid arthritis or inflammatory bowel 
disease could be beneficial for majority of the patients. Thus controlling the amount 
of TNF in our body is very crucial to reduce the chances of autoimmune diseases (24, 
25,26,27). 
  An autoimmune disorder occurs when the body’s immune system attacks and 
destroys healthy body tissue by mistake, thus the ability to discriminate between self 
and non-self antigens is vital to the functioning of the immune system as a specific 
defense against invading microorganisms. Failure of the immune system to "tolerate" 
self-tissues can result in pathological autoimmune states leading to debilitating illness 
and sometimes death(1). It's estimated that 5 to 8 percent of people in the United 
States are living with an autoimmune disease. Researchers aren't sure why, but the 
prevalence of autoimmune diseases seems to be increasing. (24). 
                             Cell signaling  
  Cells, particularly lymphocytes, are subject to a variety of external stimuli and 
their responses to those stimuli are responsible for a cell responding in a particular 
way. For instance, the same stimulus, antigen binding with high affinity to a cell 
surface antibody, can cause an immature B cell to either attempt receptor editing or 
undergo apoptosis (1). In a mature B cell this stimulus would trigger cell division and 
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subsequent metabolic changes to make the daughter cells into antibody secreting 
plasma cells. But the exact number of divisions, the antibody-secreting capacity of the 
plasma cell, the life-span of the plasma cell, and a host of other factors are all ‘tuned’ 
by the signaling machinery activated in individual cells. So, in order to understand the 
immune system and B cell function, we must understand cell signaling. 
  In general, cells that do not undergo proper gene rearrangement do not receive 
specific developmental signals from their surrounding environment and therefore 
undergo a programmed cell death also called apoptosis(23). Cells that undergo 
apoptosis loose contact with their surrounding tissue. Their cytoplasm and nucleus 
condense resulting in cell shrinkage. Their mitochondrial membranes become more 
permeable and loose membrane potential, releasing cytochrome c into the cytoplasm 
(28). The nucleolus and nuclear envelope break down, resulting in condensation of 
chromatin.  The plasma membrane ultimately divides the cell into apoptotic bodies by 
forming invaginations and protrusions. These dying cells signal their apoptotic state 
to the surrounding tissue, which assists in the degradation of apoptotic bodies by 
phagocytosis (28). 
  Necrosis is also a form of cell death, where cells die in response to physical 
and chemical injury. Necrotic cells take up water and swell up. Swelling causes the 
cell to burst open releasing all its contents into the surrounding environment (28). The 
physiological effects differ greatly from those of apoptosis. Since a necrotic cell 
releases its contents, there is a high chance that infected cells may release pathogens 
that end up spreading infections. Additionally, the release of cytochrome c by 
mitochondria could cause tissue damage and activate auto reactive lymphocytes.  
Thus apoptosis is the preferred mechanism to eliminate B cells (28). 
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  There are two major pathways through which a cell can initiate apoptosis; loss 
of signal transduction, or receptor initiated signal transduction in which healthy cells 
are instructed to die (23). As stated earlier, the process of gene rearrangement and 
gene conversions frequently results in errors.  Cells that do not produce in-frame Ag 
receptor end up undergoing apoptosis. Additionally even activated lymphocytes can 
undergo this type of cell death at the end of an immune response once the antigen and 
inflammatory response have been removed from the system (23).  
  In contrast, a healthy cell whose death is induced by cell surface receptors 
requires caspase activation (23). Apoptosis initiated by the death domain (DD) 
containing death receptors of the Tumor necrosis factor receptor family (TNFR) is an 
example of this type of cell death receptor (29,30). Once the death receptor is bound 
by its respective ligand, the death domain of the cytoplasmic tail binds to the death 
domain of an adaptor molecule. An adaptor molecule plays a key role in linking death 
receptor and downstream members of a signaling pathway. For example, the adaptor 
protein FADD links the surface receptor to intracellular procaspase, activating the 
caspase and initiating cell death (1,31). 
  Fas (CD95), a member of the TNFR family, is also an example of a death 
receptor. Its role is to trigger apoptosis in cells. Fas is activated by its ligand or 
agonist Ab (antibody) which results in the recruitment of Fas- associated death 
domain protein (FADD) via their death domain. This results in trimerization of the 
FAS molecules. Fas and FADD interact via their C terminal death domain, which 
exposes FADD’s N terminal death effector domain (DED). The DED of FADD in 
turn interacts with the DED domain in procaspase 8. This binding of procaspase 8 and 
FADD results in cleavage of procaspase 8, forming active caspase 8 and initiating a 
protease cascade.  In this cascade, caspase 8 activates downstream caspases such as 
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caspase 3 and 7. The final stage is when caspase activated DNase enters the nuclease 
and cleaves the DNA resulting in DNA fragmentation, one of the main characteristics 
of an apoptotic cell (29, 32-34) 
              Immune cell responses are controlled by many receptors that are capable of 
curbing the activity of the cell. The first signal originates from the antigen receptor in T 
and B cells and these early signals are tempered by a number of activating and 
inhibitory receptors, which ultimately play an important role in determining the 
immune response. It is important to note that in many cases inhibitory and activating 
receptors can be from the same receptor family.  The immunoreceptor tyrosine based 
inhibition motif (ITIM) is one of the significant features of many inhibitory receptors. 
It consists of a six amino acid sequence containing tyrosine(Y) with conserved N 
terminal(Y-2) and c terminal (Y-3) residues (35). On the other hand, activating forms 
contain immunoreceptor tyrosine based activation motifs (ITAM), where tyrosine 
phosphorylation forms a docking site for kinases (36). The activating receptors have a 
short cytoplasmic tail and have transmembrane residues that help in the association 
with adaptor molecule containing ITAM(31). Immunoreceptor families with inhibitory 
and activating members include Fc receptors (36). An example to explain this process 
would be CD40 co stimulatory molecule. CD40 is constitutively expressed on APC’s 
and CD40 ligand (CD40L) is induced on T cells upon Ag recognition. Thus the 
interaction between CD40 and CD40 L also enhances T cell responses. Even though 
the mechanism remains unclear, it is believed that CD40:CD40L interactions serve to 
upregulate interactions of other CD’s like CD 80 on APC’s and to induce the 
production of cytokines such as IL-12 which ultimately promotes T cell differentiation. 
Researchers have shown that CD28 and CD40L play distinct and complimentary roles 
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in T cell activation and also suggests why blocking both these costimulatory pathways 
may have distinct effects on T cell response to Ag (37). 
 
 
SLAM (Signaling lymphocyte activation molecule) 
 A particular family of molecules is called SLAM (signaling lymphocyte 
activation molecule) and is known to be related directly to B cell biology. It is a 
family of nine immunoglobulin like receptors, which includes SLAM F1, SLAMF3, 
SLAMF4, SLAMF5, SLAMF6 and SLAMF7 ( 38,39).These receptors are known to 
be closely related to CD2 family and are expressed in various immune cell types. 
SLAM/CD46 is also immune cell specific cell receptor for measles virus in humans 
(40). The SLAM family is characterized by having two extracellular Ig domains and 
an intracellular sequence of amino acids called the immunoreceptor tyrosine switch 
motif (ITSM) (41). SLAM family members have shown to be been involved in the 
deletion of lymphocytes and recent studies suggest that SLAM is associated with 
autoimmune diseases in humans and mice (40,42). X linked lymphoproliferative 
disease (XLP) 1 is a type of immunodeficiency caused by mutation or deletion in SH2 
DIA gene which encodes SLAM associated protein (SAP) (41). Loss of SAP activity 
is associated with severe natural killer (NK), T and B cell abnormalities and reduced 
antibody production (40).   Studies have shown that SLAM F genes play a major role 
in mediating the loss of tolerance to nuclear antigens and also in the development of 
auto immunity in Sleb mice (43). Recent studies have also shown that polymorphisms 
in SLAM family genes are implicated in both murine and human lupus (43). A 
recently published report found that the LY 108/SlamF6 gene is implicated in the loss 
of early B cell as well as T cell tolerance. Ly108 regulates T and B cell interactions 
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by modulating positive and negative signals through SAP(43). Collectively this data 
indicates that SLAM/CD2 family members can have a variety of important impacts 
on lymphocyte function and survival(43) and underscores the complexity of 
lymphocyte signaling during both development and during an ongoing immune 
response 
 Recent studies have identified chicken SLAM family of receptors and 
characterized five members of the family as well as the Sap adaptors (38). Three 
chicken SLAM genes were identified on chromosome 25 in the chicken genome. The 
researchers have confirmed that out of five chicken SLAM genes, three of them could 
be assigned to human counterparts and therefore named as SLAMF1, SLAMF2 and 
SLAMF4 (38). Although they share only 24 to 28% identity with the mammalian 
genes, they possess highly conserved cytoplasmic motifs in the case of SLAMF2 and 
SLAMF4. Studies have shown that chicken SAP is similar to mouse SAP; they are 
identical in length and both feature a SRC homology domain. Src family protein 
tyrosine kinases are known to participate in signaling through cell surface receptors 
that lack intrinsic tyrosine kinase domain. However it is interesting to note that human 
SAP is much shorter. These results suggest that chicken SLAM receptors employ 
similar signal transduction pathways as described for mammals(38).Thus suggesting 
that SLAM receptors in chicken have the ability to modulate the immune response in 
a similar fashion as in mammals. Scientists are still testing to what extent these 
molecules impact cell death signaling (39,40,44). 
 Studies need to be done on how these molecules activate death signaling. 
Recently scientists have also reported that SLAM receptors play important roles in 
regulating both innate and adaptive immune response by virtue of their ability to 
transduce tyrosine phosphorylation signals through immunoreceptor tyrosine based 
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switch motif sequences (45-51). The process by which cells respond to signals is an 
interesting area of research. In general during signaling, proteins interact in a specific 
way, moving the signal from membrane bound proteins to cytoplasmic proteins. Work 
on the src kinase family of protein tyrosine kinase have defined two types of protein 
interacting domains; SH2 (src homology 2) domains interact with phosphorylated 
tyrosine residues and SH3(src homology3) domains interact with proline rich 
sequences (PXXP) about which I am going to talk in the next couple paragraphs (52). 
Src Family Kinases(SFK): 
 The Src family of protein kinases (SFK) plays a crucial role in regulating 
signal transduction pathways via diverse cell surface receptors. The name src derives 
from the discovery of the prototypical src gene in the Rous sarcoma virus, a chicken 
tumor virus discovered in 1911 by Peyton Rous (53) Src family kinases are controlled 
by receptor protein tyrosine kinases, integrin receptors, G protein coupled receptors, 
antigen and Fc coupled receptors, cytokine receptors and steroid hormone receptors. 
Src kinases are usually anchored in the cell membrane by a glycophosphatidyl inositol 
(GPI) linkage, tethering the kinase to the inner leaflet of the plasma membrane and 
associating the kinase with lipid rafts in the membrane. Studies of src proteins 
identified three major domains common in src family members, SH2 (src homology 
2), SH3 (src homology 3) and SH1 (kinase catalytic domain). (54,55). Subsequently, 
SH2 and SH3 domains have been identified in a wide variety of non-src proteins. The 
SH3 domain consists of approximately 60 amino acids and has been recognized in 
several proteins(56,57);many of these are involved in signal transduction such as 
phospholipase C and phosphatidylinositol 3 kinase (PI 3-K) (55).  
 Src homology 3, which is also known as SH3 domain, binds to target protein 
through sequence containing proline and hydrophobic amino acids. (55).  The SH3 
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domain is known to have a characteristic fold which consists of five or six beta 
strands arranged as two tightly packed anti parallel beta sheets (58).  The surface of 
the SH3 domain consist of a flat, hydrophobic ligand binding sites consists of three 
shallow grooves defined by conservative aromatic residues in which the ligand adopts 
an extended left handed helical arrangement. The region bound by SH3 domain is 
proline rich and contains PXXP as a core conservative binding motif. The function of 
the SH3 domain is not very well understood but it may mediate many diverse 
processes such as increasing local concentration of proteins, altering their subcellular 
location and mediating the assembly of large multiprotein complexes (59). It is 
interesting to note that the SH3 domain is conserved throughout evolution from yeast 
to mammals and different lines of evidence suggest that SH3 domain would be 
involved in protein-protein interactions. Scientist have tried hard to resolve the 
structure of many SH3 domains (60) and all of them show similar folds. The SH3 
domain is perhaps the best-characterized member of the growing family of protein-
interaction modules. (22, 45, 52, 54, 56, 61) 
 An important feature to note in any signal pathway is the ability to interact 
with each other in some sort of specific way, which allows signals to move from a 
membrane bound protein to cytoplasmic proteins and it is also important to note that 
signaling processes involves protein conformational change and which involves 
exposing areas like PXXP (SH3) motifs (52). Research in signaling transduction can 
be challenging because different proteins have different pathways and they all might 
interact in additive, synergistic or antagonistic ways (61) and thus SH3 domain 
becomes an important part of my project. 
 To summarize, we know that B cells can bear potentially auto reactive 
antibodies and that these cells must be eliminated early in B cell development. We 
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also know that in order to receive a signal for elimination B cells must use signal 
transduction pathways. Yet, signal transduction is inherently complex and we must 
have clear experimental models to tease apart these pathways. So to understand how 
signal transduction pathways might trigger the death of B cells we need a model 
system to study B cells during the deletion event.   
Bursa of Fabricius. 
 The chicken has a unique organ, the bursa of Fabricius, which is completely 
devoted to producing B cells. The bursa epitomizes a model system where we can ask 
questions about signals monitoring the life and death of B cells at this stage of 
development (62). The bursa of Fabricius also provides the necessary 
microenvironment for diversification of avian Ig genes (63). Chemical or surgical 
ablation of the bursa early in development results in poorly diversified Ig genes and a 
consequent defect in humoral immunity with reduced antigen specific Ig responses 
(64). The bursa begins developing between day 3 and 5 embryonic life and forms 
from epithelial invaginations from a dorsal appendage of the cloaca. It remains 
connected to the gut by bursal duct. Because of this connection, external gut antigens 
might be able migrate to bursa.  Between days 8 and 10 of embryonic development 
mesenchyme cells are able to migrate and adhere to the epithelium. There they form 
epithelial buds by increasing in volume. These buds ultimately develop into bursal 
follicles at 10 and 11 days; between days 8 and 14 B cell precursors migrate from 
spleen to the bursa. Precursor B cells undergo Ig gene arrangement while in the 
embryonic spleen (6), so they enter the bursa as B cells with rearranged VH and VL 
loci. Once the precursors B cells reach the bursa, they start to proliferate and form 
approximately 10
4
 lymphoid follicles that will eventually hold about 10
5
 lymphocytes 
each. However it is important to note that there is no migration from one follicle to 
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another (6,9). B cells also undergo a series of gene conversion events while 
undergoing proliferation in the bursa to develop a wide variety of antigen specificities 
as mentioned earlier. Proliferation of B cells and gene conversion of Ig genes in the 
bursa continues until about 16 weeks after hatch (63). 
 Most of the B cells within the bursa die and only 5% successfully leave the 
bursa and participate in the immune system (11). Chickens lacking the bursa 
microenvironment exhibit only a few mature B cells that had differentiated from B 
cell precursors and a low rate of gene conversion. The low diversity of the antibody 
genes in these animals indicated the important role of the bursa in the proliferation 
and diversification of the chicken B cell repertoire (64). Chicken gene conversion was 
initially believed to occur only in birds but now it is clear that a number of animals, 
such as rabbit and sheep, also use this mechanism to develop an immunoglobulin 
gene repertoire.(66). Bursectomized chickens also exhibited low level of surface 
immunoglobulin positive (sIg) B cells in the periphery compared to their non  
bursectomized counterparts at 10 weeks of age (64). However they were able to 
produce some Ig but they lacked the ability to produce specific antibodies upon 
repeated immunization. Even upon in vitro exposure to bursal epithelial cells or bursal 
epithelial conditioned media at 10 weeks of age, B cells that had matured in the 
absence of the bursa were still unable to produce specific antibodies. This indicates 
that not only bursa, but also the early timeframe in which developing B cells interact 
with bursal epithelial cells is critical for proper gene conversion as well as B cell 
proliferation.  Furthermore, B cells in the bursa are more or less at the same stage of 
development, they possess antibody on their surface (8,9). 
 Interestingly, birds can also develop antibody-mediated autoimmune disease 
just like humans, indicating that self-reactive lymphocytes are normally censored 
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within the bursa (63). Loss of Ig expression appears to precede apoptosis in the bursa, 
which would explain the death of cells incapable of translating Ig transcripts(6,9). 
Within the bursa B-lymphocytes are particularly susceptible to apoptosis, yet appear 
to be kept viable by interactions with epithelial cells within lymphoid follicles. This is 
the reason why bursa represents a model system where we can question the signaling 
molecule(s) that control the life and death of B cells at an early stage in their 
development and prior to encounter with foreign antigens(67,68).  
 Though there are some clear differences between B cell development in 
humans and chickens, the overall signaling process remain the same and thus the 
chicken remains an interesting and informative model for the study of lymphocyte 
development. 
chB6 
                                   Understanding B cell development in mammals has been assisted by the 
development of monoclonal antibodies, which can identify unique protein expression 
patterns on developing B, cells, allowing scientists to narrow down the different 
stages within a cell lineage. Gilmore et al. identified a marker present on avian B 
cells, initially known as Bu-1 (Bursal antigen 1) now called chB6 (69) In these studies 
two allelic forms of Bu-1 were identified, Bu1a and Bu1b, these alleles being co 
dominant. However the function of Bu1 was never identified. Studies by Houssaint et 
al (70) found out that chB6 is expressed on the surface of virtually all B-cells 
throughout ontogeny with the exception of plasma cells in the Harderian gland. Low 
levels of this molecule are also found in a subset of macrophages in bursa, intestine 
and liver. chB6 is found on the early B cell precursor in the day 8 embryonic spleens, 
which makes it a B cell marker (70,71). The presence of chB6 on chicken B cells 
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suggests a physiological function, yet no known function was reported until the late 
1990’s.  
  Cloning of the chB6 cDNA molecule showed that it is a 70 kDa type 1 
transmembrane protein with a highly glycosylated extracellular region and a 105 
amino acid intracellular component notably rich in proline and acidic residues. chb6 
resides of the surface of cells as a disulfide liked homodimer (5, 72)  During the initial 
cloning it was found that there are actually at least three alleles, of chB6; chB6.1 
(Bu1a), chB6.2 (Bu1b) and chB6.3 (4,72,73).  The majority of the differences 
between these alleles of chB6 lie in their extracellular domain and they are equally 
distinct from one another. The intercellular domain is highly conserved, suggestive of 
cell signaling function (73). 
                         Initially chB6 did not appear to have any homology with known mammalian 
counterparts and was thought to represent a unique B cell marker for chicken (73). In 
fact, it was described as a molecule of ‘unique structure’. Researchers have shown 
some similaries between chB6 and CD2 family, both the molecules possess two Ig 
like domain in their extracellular domain (44).  The gene which encodes chB6 lies 
within 20Kb of the CD2 gene on chicken chromosome1, in agreement with the 
clustering of CD2/SLAM genes noted in mammals. However chB6 has no 
intracellular tyrosine residues, and thus no ITSM (Immune tyrosine switch motif) . 
The chB6 cytoplasmic domain however shows slight similarity to SLAM/CD2 family 
members since both the molecules have two extracellular Ig domains and also have 
conserved proline rich cytoplasmic domains and research indicates that this is an 
intrinsically disordered protein. Intrinsically disordered domains are highly 
characteristic of proteins with signaling functions (44) 
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  In 1997 it was determined that chB6 was capable of triggering apoptosis when 
stimulated with anti-chB6 antibody(4).  This response was also replicated when the 
molecule was transfected into murine cell lines, which implies a conservative death 
mechanism among species. Binding to chB6 leads to rapid cell death suggesting that 
chB6 could act as a death receptor. (4, 74). Our lab (Funk Lab) has shown that chB6 
can mediate a death signal that can activate caspase 8 and caspase 3, both integral 
cysteine proteases commonly activated in apoptosis pathways. This apoptosis could 
be inhibited by overexpression of the anti-apoptotic bcl-2 family member bcl-xL(5).  
In murine cells signals from growth factor also inhibits chB6 mediated apoptosis(74). 
Inhibitors of caspase 3,8 and 9 activity inhibit apoptosis in cells treated with anti 
chB6(5). 
  All these studies suggest that there are other death pathways which involves 
activation of caspase 8(33, 75) but function independently of death domains. The 
association of chB6 with the CD2/SLAM family of proteins raises interesting 
hypothesis about a possible role as a co-stimulator or ‘tuner’ of immune signaling. 
The Funk lab has also shown that chB6 induces apoptosis in a transfected mammalian 
cell line and apoptosis is inhibited by over expression of the anti-apoptotic protein 
Bcl-xL (5). The data also showed that when Ab binds to chB6 results in cleavage of a 
receptor associated caspase, caspase 8, and results in a subsequent rise in the relative 
amount of the active form of caspase3(74)  
 Even though there is no obvious homolog to chB6 based on nucleic acid or 
overall protein sequence, there has to be an underlying conserved function which 
enables chB6 to trigger apoptosis in both avian and mammalian cells. Funk lab has 
also shown that chB6 triggers cell death in human Jurkat T cells (P.E Funk 
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unpublished data). As presented here, the dynamics of B cell development in the 
bursa continues to be an viable model of lymphocyte development (76) 
Statement of Proposed Research: 
  The process of signaling via the novel avian molecule chB6, which leads to a 
rapid cell death, became the main motive for this research project. This cell death was 
via apoptosis. In fact, recent work at Dr. Funk’s lab indicated that chB6 has some 
similar structure with the SLAM/CD2protein family(44). Past work in the Funk lab 
identified four new alleles of chB6 in chicken and one allele in turkey, all showed 
little variation in the cytoplasmic domain, further suggesting an important function 
(Funk, unpublished observations). Additionally, chB6 is found on the surface of B 
cells in lipid rafts, a membrane domain associated with signaling function, in close 
association with the B cell antigen receptor(44).  In fact crosslinking chB6 resulted in 
stronger up regulation of integrin adhesion than cross-linking of the BCR.  
Collectively, this strongly suggests that chB6 is an integral part of BCR signaling in B 
cells, and one outcome of that signaling is apoptosis (44, 63, 74).   
 The Funk lab has characterized a series of truncations of the cytoplasmic 
domain of chB6 and identified the critical death-signaling region to a 15 amino acid 
stretch (figure 4). If this region is eliminated chB6 can no longer trigger apoptosis. 
Initial work has focused on a sequence of charged amino acids in this region, the 
sequence DHVEA (Figure 3)(Funk unpublished) . In fact a single amino acid change 
of E to Q within this region can reduce the cell death up to 50% (Funk, unpublished 
observation). At the C terminal region of this 15 amino acid is a consensus SH3 
binding site (PPMP).  Knowing that SH3 binding sites are critical in a variety of 
signaling contexts we proposed that this SH3 binding site is required for apoptosis 
signaling by chB6.  Since previous studies have used mutagenesis of SH3 binding 
 27 
sites to study their function we proposed to use this method to study the role of the 
SH3 binding site. Mutation of this binding site (SH3) to disrupt the protein- protein 
interaction has been used in other studies(61).  
We generated a single amino acid (proline to alanine) change in the SH3 
binding site in chB6. Since there are two prolines in an SH3 binding site (PXXP), we 
generated mutations with sequences PXXA, AXXA. These mutants were introduced 
into BK3a cells and single cell clones were isolated. We used site directed 
mutagenesis to introduce point mutations and clones were generated.  To test the 
ability of these mutant chB6 molecules to induce apoptosis, we introduced them into 
BK3a cell line isolated single cell clones. These single cell clones which  were 
incubated in the presence of antibodies to chB6 for two hours and cell death then will 
be measured with the of the vital dye trypan blue (dead cells stain blue )(4). 
 
 Our hypothesis was “mutation in SH3 binging site will have an effect on cell 
death” our results showed that mutation in SH3 binding side reduces cell death 
significantly and this study is one of the first evidence which showed that SH3 
binding side is an important area for cell signaling. This work is continuation of the 
Funk lab’s previous work to understand death signaling by chB6 and its regulation in 
B cells. 
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Materials and Methods:  
Primer Design  
Mutagenic Oligonucleotide primers for this project were designed individually 
according to the need of the project.  The SH3 binding motif PPMP at position 279 to 
282 in the polypeptide chain was targeted to create alanine substitutions at position 
279, 282, and 279 plus 282. Primers designed were 30 bases in length for 
P272A,P282A  and 25 bases for P 279A with a melting temperature (TM) of 70.7C 
and 68  C  using Agilent technology. The following formula were used to estimate 
the TM of primers; TM= 81.5 +0.41(%GC)- (675/N) -% mismatch where N is the 
primer length in bases. The desired mutation was inserted in the middle of the primer 
with ~ 10- 15 bases of correct sequence on both sides.  The sequences of the primers 
are shown in appendix 1.  
 
PCR amplification  
 Primers (P279A sense-P279A antisense, P282A sense- P282 antisense) were 
designed to amplify the sequence including the cytoplasmic tail portion of chB6. PCR 
reactions were prepared using the Quik Change Mutagenesis kit (Agilent technology, 
Santa Clara, CA).  Primers were diluted to 50pmol per PCR reaction.  ChB6.2 
template DNA was diluted to a concentration of .7μg/ul per PCR reaction.  The 
reaction mix consisted of 0.1 mM of each dNTP, 1.5 mM of MgCl2, and 2.5 U Taq 
Polymerase in a total volume of 50μl.  The PCR cycle parameters were set as follows: 
the first cycle held at 94.0°C for 3 minutes, followed by 29 cycles of 30 second 
periods at 94.0°C, 30 seconds at 62.0°C, and 30 seconds at 72.0°C; the final two 
cycles held at 72.0°C for 5 minutes each. The amplification products were then 
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digested with Dpn 1 for 1 hour at 37 degrees C. This procedure digests the parental 
(i.e. the non-mutated supercoiled dsDNA). 
 The experimental reactions were transformed into XL1 blue super competent 
cells and plated on LB agar plates containing 50μg/ml ampicillin.  Colonies were 
selected from these plates and added to tubes each containing 5ml LB broth and 5ul 
ampicillin.  These mixtures were incubated overnight at 37.0°C. 
 
Minipreps of chB6 Transformants 
DNA was isolated from overnight culture using QIAprep Spin Miniprep Kit (Qiagen, 
Valencia, CA). To verify the PCDNA 3 vectors, which contain the chB6.2 insert, 
DNA was digested with BamH1 restriction enzymes and resolved on an agarose gel.  
The presence of single nucleotide changes was confirmed by sequencing at 
SeqWright Genomic Services Sequences, Houston Texas. Translations of each 
mutation are given in Appendix 1.  
 
Cell lines  
The bursa lymphoma cell lines were used which included LSCC-DT40 and LSCC-
BK3a. DT40 Cells were grown in DMEM (Life Technologies Laboratories, Grand 
Island NY) supplemented with 6% tryptose phosphate broth (Life Technologies), 10% 
New born bovine serum (NBS) (Hyclone) 4% chicken serum(sigma chemical co.), 
and 10mM HEPES ph 7.3 (life technologies). BK3a cells were grown in DMEM 
supplemented with 6 % tryptose phosphate broth, 6% NBS,1%  chicken serum and 
10mM HEPES, ph 7.3. The cells were split approximately thrice per week.  
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Transfection 
 BK3a cells were transfected with the help of electroporation (250 V, 950uF) with 
pcDNA3 vector (Invitrogen, San Diego,CA) containing either the cDNA encoding 
chB6.2(accession no. X92867), mutants p282A,p279Ap282A or with no insert served 
as our negative control.  After electroporation the mixture was rested for 10 minutes 
at room temperature. Next the transfected cells were transferred into culture flask with 
BK3a media. Stable transfected cells were selected using G418, neomycin  at 1 unit 
/mL  
 
Immunofluorescence  
To confirm the presence of chB6 on the surface of transfected cells, 
Immunofluorescence was performed. 
10
6
 cells were suspended with primary antibody FU5-11G2(mouse anti-chB6.2 
ascites) (4), diluted 1:200 and incubated for 20 minutes on ice. The cells were then 
washed twice and resuspended in  FITC- conjugated anti mouse IgG secondary 
antibody 1:200 (Millipore, Temecula, CA) and incubated on ice for 20 minutes. After 
20 minutes the cells were washed twice and re suspended in PBS. 
Immunofluorescence was viewed via epifluorescence microscope. 
 
Single cell cloning   
Single cell cloning was performed as described by (John A Ryan PhD, Corning 
incorporated Life science). Cell suspension at 2x10
4
 cells/mL in BK3a media were 
used. Using an 8 channel micro pipettor 100 uL of the medium were added to the 
wells in the 96 well plate except A1 which was left empty. 200 uL of the cell 
suspension were added to the A1 well, then using a single channel pipettor 100ul were 
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transferred quickly from the first well to the well B1 and was mixed by gently 
pipetting. Using the same tip, 1:2 dilutions were repeated down the entire column 
disregarding 100ul from H1 so that it ends up with same volume as the wells above it. 
With the 8 channel micro pipettor an additional 100 uL of medium were added to 
each well in column 1 making the final volume of the cells and medium up to 200 uL/ 
well.  Then using the same pipettor 100 uL were quickly transferred from wells in the 
first column (A1 through H1) to those in the second column (A2 through H2) and 
were mixed with gently pipetting. Using the same tips, 1:2 dilutions were repeated 
across the entire plate and discarding 100ul from each wells in the last column (A12 
through H12) so that all the wells end up with 100 ul of cell suspension. The final 
column was brought up to 200Ul by adding 100 ul medium to each wells. The plates 
were incubated at 37 C in a humidified CO2 incubator. After 7 to 10 days, clones 
were identified and detectable by microscopy. Single cell clones were transferred to 
flasks with 10ml media plus G418 for expansion. Single cell clones were confirmed 
by immunofluorescence. 
 
Western Blot  
Cell lysate: 
10
7
 cells were resuspended in lysis buffer (RIPA buffer) which contains protease 
inhibitor. The mixture was incubated in ice for 30 minutes and spun for 30 minutes. 
Supernatant was transferred to a clean tube for western blotting. To best compare 
protein expression levels in different clones the cells were lysed at 5 X 10
7
 cells per 
milliliter. Proteins concentrations were determined by the BCA method (Pierce 
Chemical, Rockford, IL). 50ug of protein were loaded per lane.  
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Protein samples were resolved in a 10% SDS PAGE gel.  Proteins were transferred to 
supported nitrocellulose membrane at 100mA for 1.5 hour.  Where needed, 
membranes were stained for 45 minutes in Ponceau S solution (Research Products 
International, Mount Prospect, IL) to confirm equal loading of samples. The 
membrane was blocked overnight in a blocking/incubation buffer of 4%  Bovine 
Serum Albumin (Fraction V) (Fisher scientific) in TBS at room temperature with 
gentle agitation.  The membrane was washed with TBS (tris buffer saline) with 0.1% 
Tween for 5 minutes.  Wash was repeated thrice.  Membrane was then incubated 
overnight at room temp with gentle agitation in primary antibody (anti EMI) 1:200 
with blocking buffer.  The primary antibody was raised in rabbits using the chB6-
specific peptide EMIADVESQENASNC.  The blot was then washed three times with 
TBS (tris buffer saline) tween solution also known as wash solution.  Secondary 
antibody, goat anti rabbit IgG conjugated (Roche, Indianapolis, IN) with either 
horseradish peroxidase or alkaline phosphatase,  was added  at a  1:5000 dilution in 
blocking/incubation buffer for 2 hours at room temp with gentle agitation.  This was 
poured off and again membrane was washed three times with TBS (Tris buffer 
saline). Peroxidase conjugate was visualized with 1-Step TMB substrate (Pierce). 
Alkaline Phosphatase conjugate was visualized with 1-step NBT/BCIP substrate 
(Pierce) for colorimetric visualization.  
 
Cell death assay:  
Cell death assays were performed as previously described (4). Briefly, transfected B 
cell clones or DT40 cells were placed in 24 well plate ( 10 
6
 cells/ well) and cultured 
with or without anti-chB6.2 antibody (FU5-11G2) ascites 1:200 or culture supernatant 
1:40  for 2 H. After two hours viable cells were determined by a trypan blue dye 
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exclusion test. Percentage of non viable cells were determined by the formula: (Non 
viable cells/ total number cells) * 100. The results were represented as mean +_ SD 
for triplicate cultures. 
 
Results:  
Previous studies are consistent with the hypothesis that chB6 serves as a 
death receptor. chB6 exists on the cell surface of most avian B cells throughout 
their ontogeny and, when stimulated with anti chB6 antibody, it executes rapid 
cell death consistent with apoptotic cell death (4, 70,71). The Funk lab has 
characterized a series of truncations of the cytoplasmic domain of chB6 and 
identified the critical death-signaling region to a 15 amino acid stretch 
(Introduction, Funk, unpublished observations). If this region is eliminated chB6 
can no longer trigger apoptosis. Initial work has focused on a sequence of 
charged amino acids in this region, the sequence DHVEA (Introduction). At the C 
terminal region of this 15 amino acid is a consensus SH3 binding site (PPMP).  
Knowing that SH3 binding sites are critical in a variety of signaling contexts, I 
propose that this SH3 binding site is required for apoptosis signaling by chB6 
and mutation of this site will result in a decreased percentage of cells undergoing 
apoptosis after crosslinking chB6.  
 In order to test this hypothesis, single amino acid changes (proline to 
alanine) were generated using site directed mutagenesis. A similar strategy was 
employed by Pawson (77, 78) to define the role of SH3 binding sites, thus site 
directed mutagenesis was our best approach since this technique allow us to 
introduce point mutation by changing a single amino acid. Following PCR with 
the mutagenic primers (Appendix 1) colonies were selected for isolation of 
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plasmid DNA. Plasmid DNA was screened by restriction digestion with Bam HI 
and Sac I to confirm the recovery of appropriately sized fragments (Figure 4). 
Plasmid DNA from two colonies containing appropriately sized inserts was 
sequenced to confirm that interested sites were mutated correctly and to 
confirm the translation of the mutated chB6 (Appendix 1 and 2), SH3 binding site 
located in the cytoplasmic tail of chB6. Two mutations were used, a single P to A 
substitution at position 282 (P282A) and a substitution of both of the consensus 
prolines at positions 279 and 282 (P279A,P282A), both mutations were made in 
the chB6.2 form. 
 Once plasmids encoding mutated chB6.2 proteins were identified, the 
mutants were introduced into BK3a cell line by electroporation and stable 
transfectants were isolated by resistance to G418. The BK3a lymphocyte line is 
derived from a Japanese line of chickens and does not express either the chB6.1 
or chB6.2 alleles of chB6 as identified by the allele-specific antibodies we have in 
the lab (4, 79). This makes BK3a an ideal cell line for our work: we can transfect 
chB6-encoding DNA into BK3a cells and confirm that our DNA is expressed (4). 
Previous work published by the Funk laboratory has used this system to study 
chB6 triggered apoptosis (4). Immunofluorescence was performed to confirm 
the presence of chB6.2 on the surface of BK3a cells after growth of stable 
transfectants.   Subsequently, single cell clones were isolated by limiting dilution. 
To confirm the presence of the mutated chB6 on the surface of the B cell 
immunofluorescence was performed again. Table 1 represents the percentage of 
immunofluorescence positive cells among a group of single cell clones. 100 %   of 
the clones expressed chB6 on its surface as identified by the chB6.2 specific 
monoclonal antibody FU5-11G2.  DT40 served as the positive control. E12, G7, 
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D9 and B 12 were the double mutant (P279A, P282A) clones (Table 1) and D10, 
D12 and C10 were the three single mutants( P282A) that were selected for 
further analysis. A total of 16 clones of P279A P282A and 15 clones of P282A 
were isolated. 
 Previous studies have shown that crosslinking chb6 with monoclonal 
antibody induces rapid cell death by apoptosis. Using this method we 
determined whether our mutated chB6 molecules could induce cell death. We 
selected three clones of each mutant for further analysis. Clones were incubated 
with anti chB6.2 for two hours at 37 C , as previously described (4), and aliquots 
were removed to asses cell viability by trypan blue exclusion.  Consistent with 
previous work in the Funk lab (4), DT40 and a BK3a clone transfected with un-
mutated 6.2 undergo rapid cell death when treated with anti-chB6.2 antibody as 
compared to cells incubated without antibody (Figure 5). However, BK3a clones 
expressing the P282A mutant of chB6.2 (clones D10, D12, C10) show no 
significant difference in the percentage of dead cells between wells incubated 
with anti-chB6.2 and treated and wells without anti-chB6 antibody (Figures 
6,7,8).  This result was consistent through three separate experiments. Likewise, 
BK3a clones expressing the double mutation (P279A,P282A)) showed similar 
results; DT40 control wells show rapid cell death following treatment with anti-
chB6.2 but the mutants (E12,B12,G7 and D9) show no significant difference in 
the amount of  cell death following by the treatment with anti-chB6.2 as 
compared to untreated cells (Figure 9,10,11,12). These results are consistent 
throughout four experiments.   It was interesting to note that one of the double 
mutant clones, clone E12, showed some experiment to experiment variability. In 
one experiment there was an increase in cell death after anti-chB6.2 in another 
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experiment wells treated with anti-chB6.2 actually showed reduced cells death. 
In two other experiments there was no difference between the groups. This was 
not seen in any of the other clones. Collectively, the results presented here are 
consistent with the hypothesis that mutation in SH3 binding site disrupts the 
protein – protein interaction and thus disrupts the death signals reducing the 
ability to cause rapid cell death. 
 One possible explanation for the inability of the mutant chB6 molecules to 
induce cell death is that the mutation altered intracellular trafficking, resulting in 
either inappropriately glycosylated, non-dimerized, or non-raft localized chB6. 
ChB6 is normally a heavily glycosylated disulfide-bonded dimer on the surface of 
avian B cells and localizes to the lipid raft microdomains of the cell membrane (5, 
44).   Since we saw excellent immunofluorescence with the conformation 
dependent FU5-11G2 antibody we thought it likely the protein was properly 
folded. Western blotting using a chB6-peptide specific antiserum (Figure 13, 14) 
revealed that all chB6 transfectants had a disulfide-bonded chB6 as seen by lanes 
run in non-reducing conditions. Furthermore, the level of glycosylation as 
assessed by the size range of chB6 was similar in all mutants as well as an un-
mutated chB6 transfectant and the DT40 control cell line. Collectively this argues 
that the mutant chB6 molecules are glycosylated normally, disulfide bonded 
normally, and traffic to the membrane normally, so any alteration is cell death 
can be ascribed to the mutation in the PPMP motif rather than a defect in protein 
folding or trafficking.  
It is possible that the defects in triggering cell death that we observe 
could be due to lower levels of chB6 expression in the transfectants. To address 
this we performed a western blot against equal proteins quantities of cell lysate 
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to compare expression levels.  To confirm equal loading the blot was stained 
with ponceau S solution (Figure 15). The blot was then probed with primary 
antibody (anti chB6 peptide) and secondary antibody (alkaline phosphatase 
conjugate). The result confirms that all of the P282A mutants had similar levels 
of expression to the control chB6.2 transfectant and were likely expressing more 
chB6 than DT40 control cells (Figure 16). Notably, the un-mutated chB6.2 
transfectant and DT40 show similar levels of cell death after treatment with anti-
chB6 so the defect in death of the P282A mutants cannot be ascribed to level of 
expression. Likewise, all of the P279AP282A mutants had higher levels of 
expression than the chB6.2 transfectant. The parent cell line for the transfection, 
BK3a, had barely detectable levels of chB6 in these experiments (Figure 14).  
 
 
 
Discussion:  
 
The majority of B cells die while still in the primary lymphoid organ in 
both mammalian and avian species (1, 12). This controlled cell death occurs in 
order to maintain a healthy population of B cells. It is crucial that self-reactive 
and non-functional developing B cells are not able to migrate into the periphery 
and cause harm to the organism. Earlier research has mainly focused on death by 
neglect as a means to eliminate cells that fail to correctly assemble either a pre B 
cell receptor (pre-BCR) or a mature BCR. These cells do not receive extrinsic 
signals from their surroundings environment which are necessary for them to 
survive (1).  
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The kinetics of B cell loss in mammals appear to be more rapid than in 
typical death by neglect models (1). In addition, the clonal deletion of 
autoreactive B cells in transgenic mouse models is more consistent with a death 
by instruction mechanism which is caused by receptor initiated signal 
transduction (1).  Thus it is interesting to know the different signals that govern 
the fate of a B cell are integrated and can result in either cell survival or cell 
death(1). Recent work in mice has implicated CD2/SLAM family proteins in 
maintaining B cell tolerance both in the periphery and in the bone marrow (40, 
43). The Funk lab have proposed that chB6 could function as a death receptor 
during B cell development in chickens to mediate a death by instruction 
response (63).  The work presented here supports the hypothesis that chB6 
interacts with a receptor initiated apoptotic pathway and extends previous work 
by showing that the PPMP motif of chB6 is essential in this pathway.    
ChB6 
Despite the majority of work currently being done in the mouse model 
system, avian models still provide unique insight into the life and death decisions 
made by developing B cells because they can be monitored during the 
development stages in which these events occur.   chB6 is a protein molecule 
which is found in all chicken B cells throughout their ontogeny and, when chB6 is 
stimulated by agonist antibodies, rapid cell death follows, leading to the proposal  
that chB6 might function as a death receptor during B cell development( 4 
69,70,71,). Signals from chB6 result in the cleavage of caspase 8 and caspase 3 
into their active forms (5, 74).  Caspase 8 and 3 are both cysteine proteases 
commonly activated in death receptor pathways (28).  Furthermore, the ability 
of chB6 to trigger apoptosis can be regulated by other signals within the cell and 
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by the anti-apoptotic BCL –xL protein (4, 5, 74,).  Collectively this argues that 
chB6 uses a signaling pathway very like known death receptors. Furthermore, 
transfection of the chB6 cDNA into mammalian cells replicates these features, 
arguing for a conserved mechanism of action (4, 74).  
However chB6 has little similarity to known death receptors so the 
mechanism which propagates this cell death is still being explored.  chB6 is a 
heavily glycosylated transmembrane protein(5). There are multiple alleles of 
chB6, all of which seem equally distinct from each other in the extracellular 
domain (73, Funk unpublished). Notably, all of these alleles are highly conserved 
in the cytoplasmic domain. The chB6 protein is 335 amino acids in length, with 
105 predicted to reside in the cytoplasm. This cytoplasmic domain is notably rich 
in proline residues (73) and acidic residues and has no tyrosine residues.  If 
portions of the cytoplasmic domain of chB6 are truncated, chB6 drastically loses 
its ability to transmit a death signal (Funk, unpublished) . Again, this data is 
consistent with the hypothesis that chB6 can function as a death receptor.   It 
was also interesting to note that within this death signaling region is SH3 binding 
site that was targeted in this study. SH3 binding site is known to mediate wide 
variety of signals which includes different growth signals and are also known to 
be involved in apoptosis (55, 56, 59, 61). Our lab wanted to know whether 
mutating SH3 binding site affects cell death and if does then it would take a step 
closer to understand the biology behind chB6 molecule. 
 
ChB6 and CD2 
While chB6 was initially reported as a molecule of ‘unique structure’, 
more recent work has suggested similarity between chB6 and CD2/SLAM 
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family(44, 73). ChB6 appears to have two extracellular Ig like domains that are 
characteristic of the CD2/SLAM family of proteins. chB6 lies about 20kB from the 
CD2 gene (44). CD2 is an adhesion and costimulatory molecule expressed by T 
cells and natural killer cells (83). In humans the CD2 protein consists of 327 
amino acids, of which 116 are located at the C terminus in a long cytoplasmic 
domain which is characterized by the presence of at least four well conserved 
proline rich regions and the striking absence of tyrosine residues (80). The CD2 
cytoplasmic domain is rich in proline residues like chB6, and these proline 
residues have been shown to be critical in CD2 signaling (80,83). Researchers 
studying CD2 protein also found out that CD2 cytoplasmic domain is highly 
conserved between murine and human’s CD2 suggesting similarities in the signal 
transduction pathways. CD2 together with CD 28 co-receptor can help in T cell 
activation thus CD2 has also been considered as a co stimulatory molecule. CD2 
triggering can also deliver mitogenic signals when T cells are cultured with 
combinations of anti CD 2 monoclonal antibodies. Early biochemical events 
during CD2 dependent T cell activation include translocation of protein kinase c 
(PKC) from cytosol to the cell membrane and an increase in intracellular free 
Ca++ levels (81). This latter phenomenon is likely to be involved in both 
activation and cell death by apoptosis and this has been demonstrated in 
glucocorticoid treated human thymocytes as well as in human cell lines. Studies 
have confirmed that stimulation of CD2 receptor by monoclonal antibody 
induces a rapid high peak in intracellular calcium levels which are able to induce 
apoptotic death in target cells (82). Although T cells from mice lacking 
expression of CD2 were initially reported to have normal activation parameters, 
a recent study suggests that CD2 may have a small role in enhancing T cell 
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activation. In fact, studies have shown that in knockout mice models where they 
lack CD2/CD28 show some profound defect in activation and proliferation of 
cells thus suggesting that knocking out CD2, disrupts CD2 clustering which plays 
an essential role in helping to form a specialized cell contact called the 
immunological synapse, this study also suggested that CD28 can induce protein 
clustering and segregation and thus functions’ very similar to CD2 (83). 
Furthermore the cytoplasmic tails of CD2 and CD28 interact with the same or 
similar intracellular protein.   
SLAM  
The SLAM (signaling lymphocyte activation molecule) sub-family of the 
CD2/SLAM family of proteins can also mediate either positive or negative signals 
(42). The SLAM family is related to CD2 in having two extracellular Ig domains 
but is distinct in having the ITSM motif (41).  In humans and mice CD2 and SLAM 
genes are clustered on the same chromosome, suggesting that they arose from 
gene duplications.  The SLAM family of receptors and their associated signaling 
adaptors play an important role in the regulating of various stages of 
autoimmunity (42). They are known to regulate lymphocyte lymphocyte 
interactions which are ultimately involved in cell mediated and humoral 
mediated immune response. Recent studies have also shown that SLAMF 
receptors function as disease modifiers and susceptibility factors of systemic 
autoimmunity. SLAM F6 has been implicated in maintaining B cell tolerance in 
the periphery in mouse models of lupus as well as in the control of autoreactive 
cells in the bone marrow (40, 43). There is some evidence that the SLAM family 
of receptors does play important roles in immunity. They provide key effects in 
multiple immune cell types. Recent studies have also shown that SLAM family 
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receptors can either promote or inhibit the functions of primary receptors and 
these alternative activities are controlled by whether or not SLAM related 
receptors co-exist with members of SLAM associated protein SAP family of 
intracellular adaptor molecules (84, 85).  
Collectively, this provides strong evidence that chB6 is a member of the 
CD2/SLAM family and suggests that it may have roles in B cell biology beyond 
promoting apoptosis. However, the uniqueness of the chB6 cytoplasmic tail 
poses interesting challenges to our experiments. The work presented here 
suggests parallels to CD2’s proline dominated signaling leading to Ca++ flux (80, 
83, 81). It has been shown that chB6 signaling in DT40 B cells leads to an 
upregulation of integrin affinity, an effect often dependent on Ca++, and that chB6 
is located in intimate association with the BCR, which can also signal via 
Ca++(44). Thus experiments to explore if chB6 signals lead to Ca mobilization and 
if the mutations created here have an impact on that Ca mobilization would seem 
well justified. Further parallels to CD2 signaling, including the activation of PKC, 
seem obvious aims for future work. Thus this study takes a step closer to 
understand the structure and characteristics of this chB6 molecule. 
Importantly, the mutant chB6 molecules here seem to traffic to the cell 
surface and be glycosylated normally. Consequently the inability to trigger 
apoptosis is not due to aberrant folding or trafficking of chB6. Subsequent 
studies to confirm that these chB6 mutants enter the lipid rafts are warranted, 
but not within the scope of this project.  However, Li et al. show that the mature, 
disulfide bonded, chB6 is exclusively in the rafts of DT40 cells (44). Since our 
mutants are disulfide bonded on the cell surface and the raft targeting CCC motif 
is not altered we expect that our mutants in fact traffic to the rafts.  
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SH3  
 The Funk lab has already identified a 15 amino acid stretch that is crucial 
for cell death and within this stretch; there lies a SH3 binding site. The region 
bound by SH3 domain is proline rich and contains PXXP as a core conservative 
binding motif. SH3 domain comprises of 60 residues and typically plays an 
important role in assembly or regulatory function (55, 56,57,58). An assembly 
role is exemplified by the adaptor protein Grb2 which is involved in the p21 ras 
dependent growth factor signaling pathway. However, the main function of the 
SH3 domain is not very well understood (45, 56,57).  They may mediate many 
diverse processes such as increasing local concentration of proteins, altering 
their subcellular location and/or mediating the assembly of large multiprotein 
complexes. Proline recognition domains are usually found in the context of 
larger domain signaling proteins. Their binding events often direct the assembly 
and targeting of protein complexes which are involved in cellular growth. The 
domain that bind proline rich motifs are critical to assembly of many 
intracellular signaling complexes and pathways (52). Studies have shown that 
Proline rich motifs are usually favored in a cell and there are numerous reasons 
for that. Firstly, for any peptide sequence to function in a binary interaction, it 
has to get exposed to the solvent and have the accessibility to the binding 
partner(61). Of the 20 naturally occurring amino acids, proline might be best 
suited for such a role. It is a well-known fact that a regular secondary structures 
such as α-helices and β-sheets that are essential for protein folding and topology. 
Consequently, proline-containing sequences are often found on the surface of a 
protein, as opposed to being buried within the core (60, 58).  A typical question 
that remains unknown whether meaningful biological outputs necessarily 
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depend on specific pairwise SH3 ligand interactions or is it more realistic to 
think of these interactions in a similar way, i.e does a particular SH3 domain or a 
ligand site simultaneously engage in multiple interactions in dynamic 
equilibrium and thus SH3 binding site became an important part of my project. 
  SH3 domains which is located in the cytoplasmic domain are small 
protein modules that mediates protein-protein interactions in signal 
transduction pathways which are usually activated through protein tyrosine 
kinases. Mutation of SH3 binding site disturbs the protein – protein interaction 
thus disturbing the signal transduction pathways downstream (86).  In general 
signal transduction refers to the ordered flow of cellular information by 
sequential engagement of regulatory molecules in order to modulate a biological 
response. In this study we have shown that SH3 binding site is important in the 
apoptotic signaling pathway, as mutation of this site eliminates the induction of 
apoptosis in BK3a cells. The present study also provides further evidence 
supporting the role of Src kinase activity in the regulation of chB6 induced 
killing.  
Notably BK3a has little to no endogenous chB6, confirming it’s utility in 
transfection experiments such as this. However, BK3a is reported as a B lineage 
cell so the absence of the B cell marker chB6 is somewhat puzzling. However, 
chB6 is not seen on a subset of B cells in the chicken, notably plasma cells. BK3a 
was derived by viral infection of chickens, resulting in the transformation of cells 
into tumor cell lines. BK3a is reported as a bursal lymphoma, so it is possible that 
BK3a transformation altered the ability to produce chB6 (79). 
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Future direction  
 Previous studies in the Funk lab have also shown that when chB6 is cross 
linked, it activated cell binding to integrin substrate. In DT40 cells, the cross 
linking BCR activates integrin dependent cell binding (44). Real time cell binding 
assay confirms that cross linking chB6 on DT40 initiates cell binding to both 
laminin and gelatin. CD2 molecules also act as integrin regulators which co 
stimulates integrin mediated cell binding during lymphocyte activation. All these 
data and studies suggest that chB6 could be a distant paralog of CD2 molecule 
and disrupting the proline residues could disturb the calcium influx thus 
reducing the cell death. 
 This research provides the groundwork for numerous other 
investigations into the function of chB6 and its importance in B cell physiology. 
The reduction in cell death supports our hypothesis that chB6 indeed works as a 
death receptor and mutating the SH3 binding site disrupts the protein: protein 
interaction and hence reduces the cell death by apoptosis. It is also possible that 
mutation in proline residues in chB6 decreases the intracellular calcium influx 
thus saving the cells from dramatic cell death. The next step would be to mutate 
the SH3 binding site and to stimulate the chB6 with anti chB6 monoclonal 
antibody and to monitor the intracellular calcium influx. Ca 2+ ATPase activity 
assay could be performed on the targeted cells. This activity can be measured on 
the membranes by sonication of the cells and then evaluation of apoptotic cell 
death could be performed. Since many death receptors propagate a death signal 
via caspase cascade with caspase 8 often being one of the first mediators 
involved in the process. It would be interesting to note whether this particular 
mutation has any effect on the caspase cascade. This would give us more insight 
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about the chB6 molecule act as a death receptor. Another interesting aim would 
be to study the integrin activation within these chB6 SH3 mutants.  The 
importance of characterization chB6 as a death receptor and understanding the 
means by which this molecule initiates a death signal is extremely important. It 
would also be interesting to examine the calcium levels after chB6 crosslinking. 
This project takes us to one step closer to understand the function of this 
molecule. 
 
Conclusion  
This work solidifies the hypothesis that chB6 interacts with a physiological cell 
death pathway and offers new experimental insights to the role of this molecule 
in birds as well as parallels to mammalian counterparts.   The life of a B cell is 
coordinated by a continuous series of checks that are mediated by signaling 
within the cell and between the cell and its surroundings. These signals will 
determine if the cell will continue development within the primary lymphoid 
organ and if it will progress to a mature B cell allowed to circulate in the 
periphery. Failure in any of these signal can have a detrimental effect on the life 
of the organism. The evidence we obtained supports our hypothesis that there is 
a relationship between chB6 SH3 binding site and cell death. This study also 
gives an early indication that chB6 could belong to CD2 family since the 
structures and functions have a number of similarities. This study also provides 
insight to the signaling pathway of developing B cells in the bursa of a chicken. 
From this, the knowledge of this pathway can be expanded so that we fully 
understand the structure and function of chB6 and what shapes the existence of 
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a healthy B cell repertoire during both development and in the periphery. A 
proper immune response is critical to the survival of all organism. 
By better understanding how the signals that result in cell death work, we 
can better understand why the signals fail to work and potentially what can be 
done to correct or prevent these issues. 
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Figure legends.  
Figure 1: VDJ recombination  
The VDJ recombination is described in the following image, Antibodies which are 
consist of two heavy and light chain are covalently connected with the help of 
disulphide bond. (1) 
 
Figure 2. Structure of an Antibody. 
This image describes the structure of an antibody and the constant and variable 
domains. (1) 
 
Figure 3. chB6 sequence: 
The underlined portion is the apoptotic sequence and the bolded letters (PPMP) 
is the SH3 binding site. 
 
Figure 4.  P282A and P279A P282A enzyme digest  
PCR primers described in the appendix were used to obtain chB.2 mutants. ChB6 
mutants were tested by running the samples on 1.2% agarose gel alongside 
molecular weight markers. Lane 1 is the  lambda marker. Lane 2 : chB6 plasmid 
DNA undigested and digested with restriction enzyme which served as the 
positive control. Lane 8 and Lane 9 represents the plasmid DNA of the single 
mutant (P282A) and lane 17, 18 represents the plasmid DNA of the double 
mutants (P279A,P282A). 
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Figure 5. Cell death of DT40 cells and BK3a cells transfected with unmutated 
chB6. 
DT 40 or a single cell clone of BK3a lymphocytes transfected with un mutated 
chB6 (6.2) were incubated with anti chB6.2  or no antibody for 2 hours at 37 C, 
100 uL aliquots were removed and cell death were determined by trypan blue 
exclusion. Data presented as mean  standard deviation of triplicate samples. 
Data are representative of three experiments. * p < 0.05 by paired T test 
 
Figure 6. Cell death of BK3a cells transfected with P282A mutant chB6 
Single cell clones of BK3a lymphocytes transfected with chB6 mutant (P282A) 
were incubated with anti-ChB6.2 or no antibody for 2 hours at 37°C, Aliquots 
were removed and cell death determined by trypan blue exclusion. Data are 
presented as mean  SD of triplicate cultures. DT40 served as the positive 
control, D10, D12, C10 were the three different clones. * p < 0.05 by paired T test, 
N.S. p> 0.05. 
 
Figure 7. Cell death of BK3a cells transfected with P282A mutant chB6 
Single cell clones of BK3a lymphocytes transfected with chB6 mutant (P282A) 
were incubated with anti-ChB6.2 or no antibody for 2 hours at 37°C, Aliquots 
were removed and cell death determined by trypan blue exclusion. Data are 
presented as mean  SD of triplicate cultures.  DT40 served as the positive 
control, D10, D12, C10 were the three different clones. * p < 0.05 by paired T test, 
N.S. p> 0.05. 
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Figure 8. Cell death of BK3a cells transfected with P282A mutant chB6 
Single cell clones of BK3a lymphocytes transfected with chB6 mutant (P282A) 
were incubated with anti-Chb6 or no antibody for 2 hours at 37°C, Aliquots were 
removed and cell death determined by trypan blue exclusion. Data are presented 
as mean SD of triplicate cultures.  DT40 served as the positive control, D10, 
D12, C10 were the three different clones. * p < 0.05 by paired T test, N.S. p> 0.05. 
 
Figure 9.  Cell death of BK3a cells transfected with P279A,P282A mutant chB6 
Single cell clones of BK3a lymphocytes transfected with chB6 mutant 
(P279A,P282A) were incubated with anti-ChB6 or no antibody for 2 hours at 
37°C, Aliquots were removed and cell death determined by trypan blue 
exclusion. Data are presented as mean ± SD of triplicate cultures,   DT40 served 
as the positive control, G7, E12 and B 12 were the three different clones. * p < 
0.05 by paired T test, N.S. p> 0.05. 
 
Figure 10. Cell death of BK3a cells transfected with P279A,P282A mutant chB6 
Single cell clones of BK3a lymphocytes transfected with chB6 mutant 
(P279A,P282A) were incubated with anti-ChB6 or no antibody for 2 hours at 
37°C, Aliquots were removed and cell death determined by trypan blue 
exclusion. Data are presented as mean +- SD of triplicate cultures,.  DT40 served 
as the positive control, G7, E12 and B 12 were the three different clones. * p < 
0.05 by paired T test, N.S. p> 0.05. 
. 
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Figure 11. Cell death of BK3a cells transfected with P279A,P282A mutant chB6 
Single cell clones of BK3a lymphocytes transfected with chB6 mutant 
(P279A,P282A) were incubated with anti-Chb6 or no antibody for 2 hours at 
37°C, Aliquots were removed and cell death determined by trypan blue 
exclusion. Data are presented as mean  SD of triplicate cultures, DT40 served as 
the positive control, G7, E12 and B 12 were the three different clones. * p < 0.05 
by paired T test, N.S. p> 0.05. 
 
Figure 12. Cell death of BK3a cells transfected with P279A,P282A mutant chB6 
single cell clones of BK3a lymphocytes transfected with chB6 mutant 
(P279A,P282A) and un-mutated chB6  (6.2) were incubated with anti-ChB6.2 or 
no antibody for 2 hours at 37°C, Aliquots were removed and cell death 
determined by trypan blue exclusion. Data are presented as mean  SD of 
duplicate cultures.  DT40 served as the positive control, E12 and D9 were 
different clones that were tested. * p < 0.05 by paired T test, N.S. p> 0.05 
 
Figure 13. Western blot of P82A cell  
Western blot probed with anti-chB6 peptide antiserum was performed. The 
figure shows an immunoblot of a gel on which 5 ul of cell lysates have been 
loaded. The gel was immunostained with an antibody that recognizes chB6 
protein. Values are indicated in kDa. + and – indicated the presence and absence 
of Beta mercaptoethanol. D10,D12,C10 are the single mutants. + or – shows the 
presence or absence of B mercaptoethanol  
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Figure 14 Western blot of p279A p282A cell  
Western blot probed with anti-chB6 peptide antiserum was performed. The 
figure shows an immunoblot of a gel on which 5 ul of cell lysates have been 
loaded. The gel was immunostained with an antibody that recognizes chB6 
protein. Values are indicated in KDA. + and – indicated the presence and absence 
of Beta mercaptoethanol. B12,G7 and E12 are the double mutants. + or – shows 
the presence or absence of Beta mercaptoethanol. 
 
Figure 15. Ponceau staining corresponding to the western blot. 
             Ponceau staining corresponding to the western blot is shown in figure 13. The 
blot of incubated in Ponceau for 45 minutes. The brightness of the band shows 
the equal loading. The Gel was loaded in the order of from left to right   G7,E12,  
D9, RB5, D12, C10, RBG C10,6.2F7,Bk3a,DT30. 
 
           Figure 16. Western Blot 
           Protein samples were loaded in 10%SDS and the figure shows an immunoblot of a gel 
on which 50ul of cell lystaes have been loaded. The gel was then immunostained with 
an antibody that recognizes chB6 protien. The order of the band as follows from left 
to right  DT40, BK3a, 6.2F7, RBG C10, D10, D12, RB5 D9, E12, G7 
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Figure 2  
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Figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIYILAGCAGAAAILVAVVSSLICCCMRRKHKFLPVPSDEEKDDGITMSVVSSEGVKSPPNGDHVEAQAAQIACPPMPDA
ARPDSGIVPQPMVEENFPVAVEPGEMPDPEMIADVESQENASNCFPDPIDN 
ChB6 Sequence, Transmembrane and cytoplasmic sections 
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Figure 4 . 
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Table 1  
Percent immunofluorescences after anti chB6 and FITC staining. This is the 
representative of three experiments 
Cell type  Total Number 
of cell  
Total number of 
immunofluorescence 
cell  
Percent 
immunofluorescences   
DT40  89 89 100% 
E12 95 95 100% 
B12 75 75 100% 
G7  67 67 100% 
D10  97 97 100% 
D12 57 57 100% 
C10  68 68 100% 
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Figure 5  
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Figure 6  
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Figure 7. 
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Figure 8 
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Figure 9. 
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Figure 10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
C
el
l d
ea
th
 %
 
NoAB
AB
N.S.                        N.S.                  N.S    
     * 
  DT40                            G7                                  E12                  B12                            
 70 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. 
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Figure 12. 
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Figure 13 
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Figure 14. 
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Figure 15 
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Figure 16 
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Appendix  
Appendix 1  
ChB6.2 sequence:  
The complete chB6.2 allele sequence ( Genbank ). 
 
 
 
Appendix1  
Sequence 1 
Double mutation P279A,P282A  
  
nnncngnnnnaanggctctttagtgctgaggagggtggaaaaagaggatgaagnaaacta 
 X  X  X  X  X  L  F  S  A  E  E  G  G  K  R  G  -  X  K  L  
tgagtttttttcaacgataccaaagtactctttacactggaagtatttgagccgttcatt 
 -  V  F  F  N  D  T  K  V  L  F  T  L  E  V  F  E  P  F  I  
gatgcctggtgcttccccaatggaactgcagacttgacttgcaacgtggacagcaacgag 
 D  A  W  C  F  P  N  G  T  A  D  L  T  C  N  V  D  S  N  E  
aacatgacattcgagtggaagctgaacaactcttggccgaatgccaacggggcttgtgtt 
 N  M  T  F  E  W  K  L  N  N  S  W  P  N  A  N  G  A  C  V  
aaggatggtgggaagaaggttcgtctggagaaaactgtgcctggggaatttgtatgtaag 
 K  D  G  G  K  K  V  R  L  E  K  T  V  P  G  E  F  V  C  K  
gttacatacaacaatggctttgtgtggaccaggcccattgtgctctcctgcagctatgga 
 V  T  Y  N  N  G  F  V  W  T  R  P  I  V  L  S  C  S  Y  G  
gaccttctgcagtacccgtggttcatctacatcttggcaggatgtgcaggggctgcggcc 
 D  L  L  Q  Y  P  W  F  I  Y  I  L  A  G  C  A  G  A  A  A  
atcctggtggctgttgtgtcctcactcatctgttgctgcatgaggaggaagcacaagttt 
 I  L  V  A  V  V  S  S  L  I  C  C  C  M  R  R  K  H  K  F  
ctccccgtaccctcagatgaagaaaaggatgatggaataacaatgtcggtggtgtccagt 
 L  P  V  P  S  D  E  E  K  D  D  G  I  T  M  S  V  V  S  S  
gaaggtgtgaagagcccccccaatggagaccatgtggaggctcaagctgcccagatcgcc 
 E  G  V  K  S  P  P  N  G  D  H  V  E  A  Q  A  A  Q  I  A  
tgcgctccaatggcagacgctgcccgacctgattcgggcatagtgccccagcccatggtg 
 C  A  P  M  A  D  A  A  R  P  D  S  G  I  V  P  Q  P  M  V  
gaagaaaatttcccagtggcagtagagcctggggaaatgccagacccagagatgatagct 
 E  E  N  F  P  V  A  V  E  P  G  E  M  P  D  P  E  M  I  A  
gacgtggaaagccaggaaaacgcttcgaactgtttccctgacccaattgataactgatgt 
 D  V  E  S  Q  E  N  A  S  N  C  F  P  D  P  I  D  N  -  C  
gacacgctcactgttccgccctgtcctgagtcccgtgacacccatcctttgcatcccata 
 D  T  L  T  V  P  P  C  P  E  S  R  D  T  H  P  L  H  P  I  
gtcttgctgtaagaattggtctgaaaaaatttagcagggggaagacgtgatgtgtcaggt 
 V  L  L  -  E  L  V  -  K  N  L  A  G  G  R  R  D  V  S  G  
ctgctaagctcatttacagggaaaaaaaaaaaatacatgtggctgcaggacctnggatcc 
 L  L  S  S  F  T  G  K  K  K  K  Y  M  W  L  Q  D  X  G  S  
atcacacnggcggccgctcgagnnnnnnnnnnnnnnnpsped 
 I  T  X  A  A  A  R  X  X  X  X  X  X  X   
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Sequence 2  
Single mutation (P282A) 
 
P  N  G  T  A  D  L  T  C  N  V  X  S  N  E  X  M  T  
ttngagnggaagctgaacaantnttggccgaatgccaacggggcttgtgttaaggatggt 
 X  E  X  K  L  N  X  X  W  P  N  A  N  G  A  C  V  K  D  G  
gggaagaaggttcgtctggagaaaactgtgcctggggaatttgtatgtaaggttacatac 
 G  K  K  V  R  L  E  K  T  V  P  G  E  F  V  C  K  V  T  Y  
aacaatggctttgtgtggaccaggcccattgtgctntcctgcagctatggagaccttctg 
 N  N  G  F  V  W  T  R  P  I  V  X  S  C  S  Y  G  D  L  L  
cagtacccgtggttcatctacatcttggcaggatgtgcaggggctgcggccatcctggtg 
 Q  Y  P  W  F  I  Y  I  L  A  G  C  A  G  A  A  A  I  L  V  
gctgttgtgtcctcactcatctgttgctgcatgaggaggaagcacaagtttctccccgta 
 A  V  V  S  S  L  I  C  C  C  M  R  R  K  H  K  F  L  P  V  
ccctcagatgaagaaaaggatgatggaataacaatgtcggtggtgtccagtgaaggtgtg 
 P  S  D  E  E  K  D  D  G  I  T  M  S  V  V  S  S  E  G  V  
aagagcccccccaatggagaccatgtggaggctcaagctgcccagatcgcctgccctcca 
 K  S  P  P  N  G  D  H  V  E  A  Q  A  A  Q  I  A  C  P  P  
atggcagacgctgcccgacctgattcgggcatagtgccccagcccatggtggaagaaaat 
 M  A  D  A  A  R  P  D  S  G  I  V  P  Q  P  M  V  E  E  N  
ttcccagtggcagtagagcctggggaaatgccagacccagagatgatagctgacgtggaa 
 F  P  V  A  V  E  P  G  E  M  P  D  P  E  M  I  A  D  V  E  
agccaggaaaacgcttcgaactgtttccctgacccaattgataactgatgtgacacgctc 
 S  Q  E  N  A  S  N  C  F  P  D  P  I  D  N  -  C  D  T  L  
actgttccgccctgtcctgagtcccgtgacacccatcctttgcatcccatagtcttgctg 
 T  V  P  P  C  P  E  S  R  D  T  H  P  L  H  P  I  V  L  L  
taagaattggtctgaaaaaatttagcagggggaagacgtgatgtgtcaggtctgctaagc 
 -  E  L  V  -  K  N  L  A  G  G  R  R  D  V  S  G  L  L  S  
tcatttncagggaaaaaaaaaaaatacatgtggctgcaggacctnggatccatcacactg 
 S  F  X  G  K  K  K  K  Y  M  W  L  Q  D  X  G  S  I  T  L  
gcggccgnnngagnnnnnnnnnnnnnnnnnn 
 A  A  X  X  X  X  X  X  X  X  X  
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Primers: 
Sequence – P 279A sense 
5 – TCT GGC ATT GGA GCG CAG GCG ATA TGG- 3 
 
Sequence P279A antisense  
5- CCA GAT CGC CTG CGC TCCAAT GCC AGA- 3 
 
Sequence P282A sense 
5-GGG CAG CGT CTG CCA TTG GAG GGC- 3 
 
Sequence- P282A antisense 
5-TGC CCT CCA ATG GCA GAC GCT GCC -3  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
